Biogen Avonex And Other Beta Interferons May Avoid Black Box Warning
Executive Summary
Avonex (interferon beta-1a) labeling will not include a black box warning despite an earlier request by FDA, Biogen said during an earnings call July 17.
You may also be interested in...
Biogen Sets Amevive Three Year Revenue Goal At $500 Mil.
Biogen expects revenue for the psoriasis treatment Amevive could be $500 mil. over three years
Biogen Sets Amevive Three Year Revenue Goal At $500 Mil.
Biogen expects revenue for the psoriasis treatment Amevive could be $500 mil. over three years
Serono Will File Rebif vs. Avonex 6-Month Data After June Neurology Meeting
Serono will submit six-month results from the Rebif vs. Avonex head-to-head study to FDA after the company's presentation at the World Congress of Neurology meeting in London June 22.